People with Parkinson’s disease are at a higher risk of simultaneous autoimmune diseases where the immune system erroneously attacks the body, according to a review study. Pooled data from multiple studies showed a significantly increased risk of Parkinson’s combined with either bullous pemphigoid, a rare skin condition, inflammatory bowel…
Older Parkinson’s patients undergoing deep brain stimulation (DBS), those in their 60s and 70s at the time of the surgical procedure, as well as those diagnosed at older ages are at a higher risk of death over the following years, according to a nationwide study in South Korea.
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild cognitive impairment (MCI) due to Parkinson’s disease. The trial is recruiting Parkinson’s patients at 16 sites across the U.S. Dubbed PRECEDENT (NCT05318937), it’s designed to investigate SAGE-718’s…
People with Parkinson’s disease have a nearly twofold higher risk of developing osteoporosis, a chronic condition marked by increased bone fragility, than healthy people, a study showed. Besides identifying for the first time Parkinson’s as an independent risk factor for osteoporosis, the researchers found five genes with diagnostic and…
Levels of the GFAP protein in blood are significantly higher in Parkinson’s disease patients with cognitive impairment — particularly those with dementia — compared with healthy people, a new study shows. According to researchers, blood GFAP levels could accurately identify Parkinson’s patients with mild cognitive impairment (MCI) who ended…
Different types of hallucinations — hearing voices, feeling a touch, and detecting smells or tastes, among others — affect a large proportion of people with Parkinson’s disease and have substantial clinical importance, according to a new review study. While visual hallucinations are a known nonmotor symptom of the neurodegenerative…
A new device called Izar that aims to help assess and train hand function for people with neurological disorders such as Parkinson’s disease is now available in the U.S., as well as in European countries including France, Switzerland, and Germany. According to its manufacturer, MindMaze, the hand-sized device is…
Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for Parkinson’s disease. The funding comes in the form of a Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM). Ryne plans to use the award…
Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test its experimental oral medication CVN424 in people newly diagnosed with Parkinson’s disease. The company announced $51 million in new funding, from an expanded round of Series B Financing, for…
“Parkinson’s Science POV,” a limited series podcast by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has garnered silver and Listener’s Choice honors at the Signal Awards’ inaugural program. The awards, honoring top 2022 podcasts globally, recognized the Parkinson’s disease series within its Science & Education category for “Limited Series…
Get regular updates to your inbox.
